<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01563913</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-006-11S</org_study_id>
    <secondary_id>2907</secondary_id>
    <secondary_id>8012</secondary_id>
    <nct_id>NCT01563913</nct_id>
  </id_info>
  <brief_title>Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids</brief_title>
  <acronym>RLID-PD</acronym>
  <official_title>Reducing Dyskinesia in Parkinson Disease With Omega-3 Fatty Acids</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to measure the safety (side effects) of an Omega 3
      Fatty acid called docosahexanoic acid (DHA) and measure the dyskinesia (involuntary
      movements) in Parkinson 's disease (PD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Levodopa induced dyskinesias (LID) are involuntary, abnormal movements that occur in most
      patients with Parkinson disease(PD) as a consequence of chronic use of the most effective
      symptomatic drug, levodopa (LD). LID can range from subtle and unobtrusive to marked and
      disabling. There are surprisingly few treatments for LID, including amantadine and deep brain
      stimulation. In many instances, amantadine is either poorly tolerated, or provides inadequate
      benefit, and only a small minority are appropriate candidates for surgery. Given the finding
      that docosahexanoic acid (the most abundant omega-3 fatty acid in the brain), delays the
      onset and reduces the severity of dyskinesia in two different animal models of LID, a trial
      of docosahexanoic acid (DHA) in PD subjects about to start LD as part of their drug regimen,
      to prevent or slow the progression of LID is warranted.

      Prior to embarking on a large trial, preliminary data about safety and tolerability of DHA in
      PD subjects is needed, and collection of this data is the primary outcome of this pilot
      project proposal. 40 subjects who have not yet used levodopa, but are about to begin it will
      be randomized to daily DHA or placebo. Safety laboratory testing, adverse event monitoring,
      DHA plasma and CSF levels as well as compliance/subject retention will be outcomes collected.

      In addition, preliminary data about modification of incidence rates will be collected and
      compared between the two treatment groups. This information will aid in calculating an
      appropriate sample size and treatment period for a larger definitive future study.

      Dyskinesia manifests overwhelmingly when plasma levodopa levels are high enough to cause
      anti-parkinsonian benefits, and lessens or stops when levodopa levels drop below a threshold.
      Thus, the subject's dyskinesia measurements must occur during a levodopa administration
      period. Dyskinesia measurement will occur during a two-hour levodopa cycle administered to
      subjects at weeks 0, 6, 24, 52, 76. It is expected that a good proportion of subjects will
      manifest dyskinesia within the two-year observation period, as previous studies using the
      most objective means to measure dyskinesia report incidence rates of 67% or greater within
      the first year of levodopa use. An instrument to measure dyskinesia developed by this center
      will be used as an additional outcome, and is expected to measure dyskinesia more accurately
      and with greater sensitivity than the gold standard methods of clinical rating scales.

      By conclusion of this pilot project, the safety and tolerability, subject retention and
      compliance, plasma/CSF levels of DHA administration will be determined. Trends in dyskinesia
      development may be measured. This will provide the needed background information to proceed
      with a future larger trial of DHA to prevent dyskinesia in PD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of DHA - Change in Blood ng/dL Levels</measure>
    <time_frame>baseline and 1.5 years</time_frame>
    <description>Therapeutic level monitoring will be accomplished by analyzing blood levels for DHA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy of DHA - Abnormal Safety Lab (CBC)</measure>
    <time_frame>baseline and 1.0 year</time_frame>
    <description>This study is seeking to determine the safety/efficacy of DHA in Parkinson's disease patients. The safety/efficacy of DHA will be determined using periodic safety lab information. Safety labs for complete blood count (CBC) were performed at each inpatient visit, reviewed by the PI, and marked as normal or abnormal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forceplate Measured Dyskinesia</measure>
    <time_frame>baseline and 1.5 years</time_frame>
    <description>Dyskinesia are abnormal movements caused by levodopa. These abnormal movements will be measured with a forceplate (a device that is similar to a door mat). Dyskinesia will be examined at all inpatient visits and area under the curves will be compared with a clinical rating scale to measure the development of dyskinesia after starting levodopa therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docosahexaenoic Acid (DHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docosahexaenoic Acid (DHA)</intervention_name>
    <description>Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>DHA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar Pill, taken for 1.5 years</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with Parkinsons disease

          -  No levodopa (Sinemet) treatment or prior exposure to levodopa

        Exclusion Criteria:

          -  Prior exposure to levodopa

          -  Unable to stand for 1 minute without aid

          -  Sensory deficits on feet

          -  Significant cognitive impairment

          -  Current use of dopamine receptor blocking medications (depakote, lithium, amiodarone,
             tetrabenazine, metoclopramide, dronabinol)

          -  Current fish oil or lutein supplementation

          -  Allergy to soy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathryn Anne Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Portland Health Care System, Portland, OR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Salem N Jr, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001 Sep;36(9):945-59. Review.</citation>
    <PMID>11724467</PMID>
  </reference>
  <results_reference>
    <citation>Péchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M; Trial Study Group. Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol. 2005 Dec;12(12):956-63.</citation>
    <PMID>16324089</PMID>
  </results_reference>
  <results_reference>
    <citation>Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484-91.</citation>
    <PMID>10816186</PMID>
  </results_reference>
  <results_reference>
    <citation>Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol. 2002 Jun;51(6):686-93.</citation>
    <PMID>12112073</PMID>
  </results_reference>
  <results_reference>
    <citation>Chung KA, Lobb BM, Nutt JG, McNames J, Horak F. Objective measurement of dyskinesia in Parkinson's disease using a force plate. Mov Disord. 2010 Apr 15;25(5):602-8. doi: 10.1002/mds.22856.</citation>
    <PMID>20213818</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 22, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <results_first_submitted>April 25, 2017</results_first_submitted>
  <results_first_submitted_qc>September 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2018</results_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinsons disease</keyword>
  <keyword>supplement</keyword>
  <keyword>DHA</keyword>
  <keyword>dyskinesia</keyword>
  <keyword>abnormal movements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from two large urban hospitals with Movement disorder specialty clinics in the NW USA over a 30 month (2.5 year) recruitment period. 34 subjects were screened. 1 subject screen failed due to prior exposure to levodopa. 33 subjects were randomized to DHA or placebo arms. 30 subjects returned and completed visit 1.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Docosahexaenoic Acid (DHA)</title>
          <description>Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: Sugar Pill, taken for 1.5 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Spouse Passed Away</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Report on the participants that were randomized and completed visit 1.</population>
      <group_list>
        <group group_id="B1">
          <title>Docosahexaenoic Acid</title>
          <description>Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years</description>
        </group>
        <group group_id="B2">
          <title>Placebo:</title>
          <description>Placebo: Sugar Pill, taken for 1.5 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.3" spread="7.6"/>
                    <measurement group_id="B2" value="67.0" spread="8.5"/>
                    <measurement group_id="B3" value="68.0" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Large Northwest American City</description>
          <units>count of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PD Symptom Duration</title>
          <description>Year of screening visit - Subjectively reported onset of Parkinson's symptoms year</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="1.9"/>
                    <measurement group_id="B2" value="4.6" spread="3.8"/>
                    <measurement group_id="B3" value="3.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <description>Number of years of education (subjectively reported).</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.0" spread="3.2"/>
                    <measurement group_id="B2" value="15.7" spread="3.1"/>
                    <measurement group_id="B3" value="15.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>DHA Intake at Screening</title>
          <description>DHA Food Frequency Scale Total - a one page questionnaire asking about total monthly dietary intake of items such as fish, shellfish, turkey, chicken, beef, egg yolks, and liver.</description>
          <units>mg/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119.9" spread="77.4"/>
                    <measurement group_id="B2" value="148.7" spread="88.1"/>
                    <measurement group_id="B3" value="134.8" spread="82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MoCA Score</title>
          <description>The MoCA is a short cognitive screening test designed to assist health care professionals for the detection of mild cognitive impairment. The MoCA is scored on a 0 to 30 scale, with lower numbers indicating more cognitive impairment. A point is added to the MoCA if the subject's education high school or less (12 years or less education). Scores ranging from 26 - 30 are normal, 18 - 26 mild impairment, 10 - 17 moderate impairment, and less than 10 severe cognitive impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.1" spread="3.8"/>
                    <measurement group_id="B2" value="24.7" spread="2.6"/>
                    <measurement group_id="B3" value="24.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Parkinsons Disease Rating Scale (UPDRS-III)</title>
          <description>This is the motor subsection of the Unified Parkinson's Disease Rating Scale (UPDRS) and is a commonly used tool to rate the symptoms of Parkinson‘s disease. Each item on the scale is rated from 0 (normal) to 4 (Can barely perform the task) several motor areas including speech, facial expression, tremor, rigidity, hand movements, agility, posture, and gait. Total score ranges from 0 to 108 with higher values on this scale represent a more severe stage of the disease.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="9.7"/>
                    <measurement group_id="B2" value="29.2" spread="10.9"/>
                    <measurement group_id="B3" value="31.9" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hoehn &amp; Yahr</title>
          <description>This is an objective staging scale for rating the clinical functioning of Parkinson’s disease patients, combining functional deficits (disability) and objective signs (impairment). This staging scale is commonly used in both research settings and clinical practice. The Hoehn &amp; Yahr is an ordinal scale ranging from 0 (no signs of disease) to 5 (wheelchair bound/bedridden). The modified version of the scale includes increments of 0.5. The HY has shown good inter-rater reliability and, although it is used worldwide, the clinimetric validity has not been established.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="2.0" upper_limit="3.0"/>
                    <measurement group_id="B2" value="2.0" lower_limit="2.0" upper_limit="3.0"/>
                    <measurement group_id="B3" value="2.25" lower_limit="2.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Levodopa Initial Dose</title>
          <description>Initial dose of levodopa (carbidopa/levodopa or Sinemet) as prescribed by treating physician in mg/day. This oral levodopa dose was prescribed clinically and is the first prescription of Sinemet (carbidopa/levodopa) that the participant ever received.</description>
          <units>mg/day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="300.0" lower_limit="150" upper_limit="400"/>
                    <measurement group_id="B2" value="300.0" lower_limit="300" upper_limit="600"/>
                    <measurement group_id="B3" value="300.0" lower_limit="150" upper_limit="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Levodopa Exposure (Equivalence)</title>
          <description>Prior levodopa exposure as measured by subjective self report and medical record review for dopamine agonists (such as amantadine, apomorphine, pramipexole, ropinirole, rotigotine). Converted to levodopa equivalence using the Parkinson's UK Levodopa Equivalent Dose Calculator. This is levodopa exposure prior to starting Sinemet (carbidopa/levodopa), prior to entry into the study, through another drug like a dopamine agonist.</description>
          <units>mg/day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="540.0" lower_limit="330.0" upper_limit="1440.0"/>
                    <measurement group_id="B2" value="187.5" lower_limit="30.0" upper_limit="1425.0"/>
                    <measurement group_id="B3" value="345.0" lower_limit="30.0" upper_limit="1425.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of DHA - Change in Blood ng/dL Levels</title>
        <description>Therapeutic level monitoring will be accomplished by analyzing blood levels for DHA.</description>
        <time_frame>baseline and 1.5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docosahexaenoic Acid</title>
            <description>Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo:</title>
            <description>Placebo: Sugar Pill, taken for 1.5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of DHA - Change in Blood ng/dL Levels</title>
          <description>Therapeutic level monitoring will be accomplished by analyzing blood levels for DHA.</description>
          <units>ng/dL - Blood</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.18" spread="50.0"/>
                    <measurement group_id="O2" value="-13.20" spread="33.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Efficacy of DHA - Abnormal Safety Lab (CBC)</title>
        <description>This study is seeking to determine the safety/efficacy of DHA in Parkinson's disease patients. The safety/efficacy of DHA will be determined using periodic safety lab information. Safety labs for complete blood count (CBC) were performed at each inpatient visit, reviewed by the PI, and marked as normal or abnormal.</description>
        <time_frame>baseline and 1.0 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docosahexaenoic Acid</title>
            <description>Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo:</title>
            <description>Placebo: Sugar Pill, taken for 1.5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy of DHA - Abnormal Safety Lab (CBC)</title>
          <description>This study is seeking to determine the safety/efficacy of DHA in Parkinson's disease patients. The safety/efficacy of DHA will be determined using periodic safety lab information. Safety labs for complete blood count (CBC) were performed at each inpatient visit, reviewed by the PI, and marked as normal or abnormal.</description>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forceplate Measured Dyskinesia</title>
        <description>Dyskinesia are abnormal movements caused by levodopa. These abnormal movements will be measured with a forceplate (a device that is similar to a door mat). Dyskinesia will be examined at all inpatient visits and area under the curves will be compared with a clinical rating scale to measure the development of dyskinesia after starting levodopa therapy.</description>
        <time_frame>baseline and 1.5 years</time_frame>
        <population>Docosahexaenoic Acid Arm: 2 participants withdrew after the 6 week visit, 4 didn't complete visit 5 due to: wife's death, too busy, new diagnosis of cancer.</population>
        <group_list>
          <group group_id="O1">
            <title>Docosahexaenoic Acid</title>
            <description>Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years</description>
          </group>
          <group group_id="O2">
            <title>Placebo:</title>
            <description>Placebo: Sugar Pill, taken for 1.5 years</description>
          </group>
        </group_list>
        <measure>
          <title>Forceplate Measured Dyskinesia</title>
          <description>Dyskinesia are abnormal movements caused by levodopa. These abnormal movements will be measured with a forceplate (a device that is similar to a door mat). Dyskinesia will be examined at all inpatient visits and area under the curves will be compared with a clinical rating scale to measure the development of dyskinesia after starting levodopa therapy.</description>
          <population>Docosahexaenoic Acid Arm: 2 participants withdrew after the 6 week visit, 4 didn't complete visit 5 due to: wife's death, too busy, new diagnosis of cancer.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Dyskinesia Present</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dyskinesia Absent</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data were collected over 1.5 years. Regular monthly phone calls were placed to participants to ask about adverse events, hospitalizations, and changes in medications. Adverse events were also gathered at the in-person visit occurring at 0 weeks, 6 weeks, 24 weeks, 52 weeks, and 72 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Docosahexaenoic Acid</title>
          <description>Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years</description>
        </group>
        <group group_id="E2">
          <title>Placebo:</title>
          <description>Placebo: Sugar Pill, taken for 1.5 years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Syncope during IV infusion leading to discontinuing infusion, ER visit with overnight Hospitalization with no findings.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <description>New diagnosis of prostate cancer.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Track Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathryn Chung, MD</name_or_title>
      <organization>VA Portland Health Care System</organization>
      <phone>5037211091</phone>
      <email>Kathryn.Chung@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

